IL33 and graft versus host disease: While we confirmed our earlier finding (29) that treatment with rIL-33 after alloHCT accelerates death from GVHD (Figure 1B), we revealed that targeting IL-12p40 after alloHCT did not provide any protection against IL-33–driven GVHD lethality (Figure 1B) or morbidity (Figure 1C).